Annual Report 2025

2 The United Laboratories International Holdings Limited Annual Report 2025 • UBT251 Injection, a Class 1 innovative drug, has been approved for phase II clinical trial in China on indication of chronic kidney disease. • The marketing application of The United Laboratories for Semaglutide Injection was accepted by the National Medical Products Administration (“NMPA”). JANUARY • UBT251 Injection, a Class 1 innovative drug, obtained clinical trial approval from the U.S. Food and Drug Administration (“U.S. FDA”) on indication of chronic kidney disease. FEBRUARY • The United Bio-Technology (Hengqin) Co., Ltd. entered into an exclusive license agreement with Novo Nordisk A/S for UBT251. • The new drug application (“NDA”) of Liraglutide Injection (specification: 3ml: 18mg (pre-filled)) and Polyvinyl Alcohol Eye Drops (specification: 1.4% (0.4ml: 5.6mg)) of The United Laboratories were approved by the NMPA. • The sterile APIs of Zhuhai United Laboratories Co., Ltd. and the amoxicillin API of The United Laboratories (Inner Mongolia) Co., Ltd. passed the official GMP inspection by Brazil’s ANVISA, injecting strong momentum into the Group’s strategic expansion into the South American market. • United Animal Healthcare debuted at the 2025 VIV Asia International Intensive Livestock Exhibition held in Thailand. MARCH • United Animal Healthcare held a launch event for “BANG CUB”, the New Zealand imported prescription cans, further strengthening its precision pet nutrition solutions. MAY • The United Laboratories participated in “the 23rd China Pharmaceutical Ingredients Exhibition (CPHI)” and was recognized as a “Premium Global Partner” and received the “ESG Corporate Responsibility Award”. • Zhuhai United Laboratories Co., Ltd. was honored with the China Patent Excellence Award for “a Refolding Method for a Glargine Insulin Precursor” (Patent No. ZL201310754124.4). JUNE • UBT37034 Injection, a Class 1 innovative drug, has been approved for clinical trial on indications of overweight or obesity by the U.S. FDA. • Zhuhai United Laboratories Co., Ltd. ranked 23rd among the “2024 Top 100 Chinese Pharmaceutical Manufacturing Enterprises in terms of Principal Business Income”. JULY CORPORATE CALENDAR OF 2025